+

WO1990000059A1 - Procede et recipient servant a la preparation et au stockage de concentres de plaquettes - Google Patents

Procede et recipient servant a la preparation et au stockage de concentres de plaquettes Download PDF

Info

Publication number
WO1990000059A1
WO1990000059A1 PCT/IT1989/000048 IT8900048W WO9000059A1 WO 1990000059 A1 WO1990000059 A1 WO 1990000059A1 IT 8900048 W IT8900048 W IT 8900048W WO 9000059 A1 WO9000059 A1 WO 9000059A1
Authority
WO
WIPO (PCT)
Prior art keywords
bag
plasma
platelet
crystalloid
solution
Prior art date
Application number
PCT/IT1989/000048
Other languages
English (en)
Inventor
Girolamo Sirchia
Paolo Rebulla
Original Assignee
Girolamo Sirchia
Paolo Rebulla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Girolamo Sirchia, Paolo Rebulla filed Critical Girolamo Sirchia
Priority to KR1019900700372A priority Critical patent/KR900701290A/ko
Publication of WO1990000059A1 publication Critical patent/WO1990000059A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0209—Multiple bag systems for separating or storing blood components
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0209—Multiple bag systems for separating or storing blood components
    • A61M1/0218—Multiple bag systems for separating or storing blood components with filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0415—Plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0427—Platelets; Thrombocytes

Definitions

  • This invention relates to a procedure for the routine preparation in closed system of platelet concentrates (PC) deprived of leukocytes and stored in a medium consisting of a mixture of natural colloid (plasma) and of crystalloid solution (called 5 thereafter "medium”), and in particular for PC storage.
  • PC platelet concentrates
  • Standard RBC concentrates and PC prepared by serial centrifugation from multiple bags and storage in a natural colloid medium (plasma), are contaminated with plasma and leukocytes, which can " determine acute and chronic side-effects in transfusion
  • PC platelet concentrates
  • PC transfusion 25 platelets in the supernatant.
  • the principal untoward effect of PC transfusion is the production of alloantibodies by PC recipients, caused by leukocytes which contaminate the PC.
  • allergic reactions to plasma proteins can occur.
  • the aim of this invention is to remove thi ⁇ difficulty by means of a procedure for blood f ractionation allowing the routine production and storage in closed system of plasma- and leukocyte- poor RBC concentrates (PLP-RBC, ie RBC containing less than 10% of donated plasma and less than 30% of donated leukocytes), and of plasma- and leukocyte-poor platelet concentrates (PLP-PC, ie PC in a medium containing about 15-40% plasma, and free of leukocytes detectable by microscope counting).
  • PRP-RBC plasma- and leukocyte- poor RBC concentrates
  • PRP-PC plasma- and leukocyte-poor platelet concentrates
  • the above crystalloid solution is preferably made (considering, for example, a volume of 40 mL) of 5.26 g sodium chloride; 2.22 g sodium acetate; 5.02 g sodium gluconate; 0.37 g potassium chloride; 0.14 g magnesium chloride; H2O for IV use qs to 1,000 mL, pH 7.4 ⁇ 0.1.
  • the procedure is carried out with a multiple bag, preferably a quadruple bag consisting of a primary bag and 3 satellite bags.
  • a multiple bag preferably a quadruple bag consisting of a primary bag and 3 satellite bags.
  • the blood contained in the primary bag is separated into a red blood cell button and supernatant plasma; this latter is transferred into one of the satellite bags, while the SAGM solution is added to the primary bag for red blood cell storage, after removing an amount of the buffy-coat (BC) layer, which is the layer between red blood cells and plasma, a layer enriched of platelets.
  • BC buffy-coat
  • the buffy-coat is transferred into a second satellite bag containing the crystalloid solution and, after a soft spin, the supernatant platelet concentrate is transferred in the third, empty satellite bag, through a cotton wool filter inserted along the tubing, which is capable of removing residual leukocytes which contaminate the platelet concentrate.
  • a platelet concentrate prepared according to this method ' can be stored for about 10 days in this bag, which is made of plastic material with gas exchange characteristics similar to those of polyolefin.
  • the above procedure and bag system for the preparation of platelet concentrates from buffy-coats (BC) and their storage in a crystalloid colloid medium can be used also with BC prepared with standard blood bag systems, by mixing 6-8 BC in a transfer bag containing an appropriate amount of the above crystalloid solution. After a soft spin, the supernatant, containing the platelets, is transferred through a cotton wool filter into a new transfer bag where it is stored.
  • the procedure derived from this invention is now described, just for the sake of example, and with no limitation to its implementation, with the aid of enclosed fig. 2 through 5, which describe the procedure steps, as performed with a quadruple blood bag, for the preparation and storage of PLP-PC and PLP-RBC from a blood donation.
  • the multiple blood bag consists of a primary bag PB and of 3 satellite bags SI, S2, S3, integrally connected to each other with flexible plastic tubes.
  • the primary bag PB contains CPD (citrate-phosphate-dextrose) anticoagulant
  • the satellite bag SI is empty
  • the satellite bag S2 which is cylinder-shaped and has a volume of 40-60 mL, contain ⁇ 40 L of crystalloid solution
  • the satellite bag S3 contains the SAGM red blood cell additive solution, and is made of plastice material with gas permeability characteristics similar to polyolefin.
  • a small (2-3 g) cotton wool filter is inserted.
  • the blood donation is collected in the primary bag PB through a collection line I, at one end of which the blood collection needle is attached7 and mixed with the CPD anticoagulant (fig. 1).
  • the blood collected in the primary bag PB is centrifuged at high speed, e.g. 3,800 rpm for 4 min in a Sorvall RC-3B centrifuge. After this centrifugation, plasma- and leukocyte-poor red blood cells are concentrated in the lower part of the primary bag PB, the supernatant plasma is contained in the higher part of the bag, and in the layer between plasma and red blood cells the vast majority of platelets are concentrated. This small layer, enriched of platelets, which separated red blood cells from supernatant plasma is defined "buffy-coat" (BC)(fig. 2).
  • the supernatant plasma (except for about 30 mL) is expressed into and stored in satellite bag S2, which is diconnected from the other bags (fig.2).
  • the crystalloid solution contained in satellite bag S3 has the following composition (reference to a volume of 40 mL): 5.26 g sodium chloride; 2.22 g sodium acetate; 5.02 g sodium gluconate; 0.37 g potassium chloride; 0.14 g magnesium chloride; H 2 0 for IV use qs to 1,000 L, pH 7.4 + 0.1.
  • the SAGM solution contained in satellite bag S3 is added to the red blood cell concentrate PLP-RBC in the primary bag PB for its storage.
  • the primary bag, containing the PLP-RBC and the satellite bag SI containing the plasma are disconnected from satellite bags S2 and S3, which are stored, integrally connected to each other, in a platelet tumbler (a rotating machine for platelet resuspension during storage) (fig.4).
  • a platelet tumbler a rotating machine for platelet resuspension during storage
  • the buffy-coat (containing the platelets) contained in satellite bag S2 can be stored at room temperature for a maximum of 48 h. If platelet concentrates are needed the buffy-coat is centrifuged at low speed, " so as to concentrate the red blood cells and the leukocytes in the lower part of the bag S2, and to collect the leukocyte-poor platelet concentrate in the higher part of satellite bag S2.
  • the cylinder shape of satellite bag S2 favors a good separation between the 2 layers above after the soft spin.
  • the supernatant PLP-PC is transferred from satellite bag S2 to satellite bag S3 (which had been previously emptied of the SAGM solution), through filter F, which removes residual leukocytes present in the platelet concentrate (fig. 5).
  • Filter F can be much smaller than traditional cotton wool filters for leukocyte removal (2-3 g instead of 17 g) because leukocyte contamination of platelet concentrates prepared from buffy-coats is much lower than that of platelet concentrates prepared with traditional methods, in which centrifugation is carried out on platelet-rich-plasma instead of platelet-rich-buffy-coat.
  • Experimental data indicate that the platelet concentrate PLP-PC prepared with the above method can be stored in the crystalloid/colloid medium for at least 10 days in a bag made of polyolefin, or of a plastic material capable of providing a gas permeability similar to that of polyolefin, with a final pH of about 7,0, hypotonic shock response of 50% and morphology score according to Kunicki of 220.
  • PC prepared with this method and invention have the following parameters after 7 days of storage: glucose consumption 1.5 mmol/L/10 platelets (compared to 2.8 of PC prepared in the medium of G. Rock), and iactate production of 3.56 mmol/L/10 9 platelets (compared to 6.09 of PC prepared in the medium of Rock). Both parameters suggest better platelet quality in our medium. In addition, platelet aggregation is better in our medium compared to that in the medium of Rock. These excellent results are mainly due to the crystalloid/colloid medium, of which a preferential composition has been given above, in which a crystalloid solution is mixed with a small amount of plasma (natural colloid) present in the buffy-coat, from which the platelet concentrate is prepared.
  • buffy-coats prepared from traditional blood collection bags, e.g. by using a triple bag made of a primary bag and 2 satellite bags, in which the red blood cell concentrate, the plasma and the buffy-coat are collected, respectively.
  • 6-8 buffy-coats prepared with the methods above or similar are collected in a transfer bag of about 600 mL volume, containing about 350 mL of the previously described crystalloid solution.
  • the platelet-rich supernatant is transferred through a small (2-3 g) cotton wool filter F into a transfer bag of about 1000 mL volume, with the same characteristics of previously described bag S3, where it is then stored.
  • - platelet metabolism can be conditioned by modifying the storage medium with the addition of possible additives
  • Both platelet and leukocyte counts of BCS-PC were significantly lower than those of 7 PRP-PC.
  • Platelet yield in BCS-PC and PRP-PC was 59 and 75 percent of donated platelets, respectively.
  • In vitro parameters of adequate platelet quality were maintained for 10 days in BCS-PC stored in 1000 mL polyolefin bags. Prolonged 5 bleeding times were reduced or corrected in 3 of 3 thrombocytopenic leukemic patients evaluated before and after transfusion of stored BCS-PC.
  • section A in vitro parameters of adequate platelet quality (pH above 6.0, morphology score above 200) were 20 maintained in BCS-PC for at least 10 days of storage in 1000 mL polyolefin bags; at this time the platelet response to hypotonic shock (HSR), a parameter related to platelet recovery and survival in normal volunteers, was still above 80 percent of values at day 1. This was not so for BCS-PC stored in 1000 mL PVC bags (section 25 B) , in which the median pH value was below 6.0 at day 3. This was associated with a complete loss of HSR and a marked deterioration of platelet morphology.
  • HSR hypotonic shock
  • PRP-PC stored in PVC satellite bags of 400 mL volume showed adequate quality preservation for at least 5 days (section C).
  • PO2 values 30 of BCS-PC in 1000 mL bags were about 2 times higher than those of PRP-PC in 400 mL bags, as expected on the basis of both a larger bag and a smaller platelet concentration in the former.
  • Platelet quality during storage in PVC deteriorated more rapidly in BCS-PC than in PRP-PC.
  • a contributory cause could have been the smaller ratio between bag surface area and PC volume in the former, determining a less efficient gas transport during storage.
  • Bleeding time (reference values 2-7 min) was reduced after BCS-PC transfusion in 3 of 3 patients evaluated, dropping from more than 30 to 9 min (6-day old BCS-PC containing 3,0 x l ⁇ 11 platelets), from 25 to 5 min (4-day old BCS-PC containing 2.8 x 10 11 platelets), and from 22 to 6 min (8 day old BCS-PC containing 3.1 x 10 platelets).
  • pre- and 1-h posttransfusion platelet counts were 17-43, 16-56 and 16-39 x q 10 /L, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Le procédé décrit, qui sert à la préparation de routine dans un système fermé et au stockage dans un milieu, constitué d'un colloïde naturel (plasma) et d'une solution cristalloïdale, de concentrés de plaquettes dépourvus de leucocytes, utilise un sac sanguin quadruple formé d'un sac primaire (PB) contenant un anti-coagulant de citrate-phosphate-dextrose (CPD), d'un sac satellite vide (S1), d'un sac satellite (S2) contenant une solution cristalloïdale synthétique, ainsi que d'un sac satellite comportant une solution additive de SAGM (ou similaire) pour les globules rouges du sang (RBC). Ledit procédé consiste à recueillir le sang dans le sac primaire (PB), à centrifuger le sac sanguin à une vitesse élevée, à transférer par extraction par pression le plasma surnageant dans le sac (S1), à recueillir 15 à 20 ml de la couche intermédiaire riche en plaquettes ('buffy-coat' (BC)) dans le sac (S2), à ajouter la solution de SAGM du sac (S3) dans le sac (PB) contenant le concentré de (RBC) à séparer les sacs PB et S1 des sacs S2 et S3, à centrifuger le sac (S2) à une vitesse de rotation modérée et à transférer le concentré de plaquettes (PC) surnageant pauvre en plasma et en leucocytes (PLP), qui s'est formé après la centrifugation, dans le sac vide (S3), à travers un filtre d'ouate (F) introduit dans le tube reliant S2 et S3, de façon à extraire les leucocytes résiduels qui contaminent le concentré de plaquettes (PC).
PCT/IT1989/000048 1988-06-28 1989-06-26 Procede et recipient servant a la preparation et au stockage de concentres de plaquettes WO1990000059A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019900700372A KR900701290A (ko) 1988-06-28 1989-06-26 콜로이드/결정성 매질속의 저백혈구 혈소판 농축물 제조 및 저장방법과 용기

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT21118/88A IT1217938B (it) 1988-06-28 1988-06-28 Procedimento per la preparazione e la conservazione di concentrati eritrocitari e piastrinici
IT21118A/88 1988-06-28

Publications (1)

Publication Number Publication Date
WO1990000059A1 true WO1990000059A1 (fr) 1990-01-11

Family

ID=11177005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1989/000048 WO1990000059A1 (fr) 1988-06-28 1989-06-26 Procede et recipient servant a la preparation et au stockage de concentres de plaquettes

Country Status (6)

Country Link
EP (1) EP0447399A1 (fr)
JP (1) JPH03505830A (fr)
KR (1) KR900701290A (fr)
AU (1) AU3847589A (fr)
IT (1) IT1217938B (fr)
WO (1) WO1990000059A1 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024157A1 (fr) * 1992-05-29 1993-12-09 Baxter International Inc. Appareils et procedes pour generer un concentre plaquettaire depourvu de leucocytes
WO1994012223A1 (fr) * 1992-12-01 1994-06-09 Haemonetics Corporation Appareil et procede de pherese des globules rouges
EP0627228A1 (fr) * 1993-06-01 1994-12-07 ASAHI MEDICAL Co., Ltd. Centrifugeuse pour la séparation de produits sanguins et ses composants
US5637082A (en) * 1996-02-22 1997-06-10 Haemonetics Corporation Adaptive apheresis apparatus
EP1450892A2 (fr) * 2001-12-05 2004-09-01 Baxter International Inc. Systemes et procedes de traitement manuel permettant de fournir des constituants sanguins conditionnes en vue de l'inactivation pathogene
US6936413B1 (en) * 2001-12-05 2005-08-30 Baxter International Inc. Methods and systems for preparing blood products
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US20100081985A1 (en) * 2008-10-01 2010-04-01 Caridianbct, Inc. Platelet Additive Solution For Leukoreducing White Blood Cells In Apheresed Platelets
CN101693039B (zh) * 2009-10-14 2011-12-14 北京普瑞博思投资有限公司 一种用于手术冲洗的药物组合物
US8808217B2 (en) 2008-04-14 2014-08-19 Haemonetics Corporation System and method for plasma reduced platelet collection
US8808978B2 (en) 2010-11-05 2014-08-19 Haemonetics Corporation System and method for automated platelet wash
US8834402B2 (en) 2009-03-12 2014-09-16 Haemonetics Corporation System and method for the re-anticoagulation of platelet rich plasma
US9095665B2 (en) 2008-04-14 2015-08-04 Haemonetics Corporation Three-line apheresis system and method
US9302042B2 (en) 2010-12-30 2016-04-05 Haemonetics Corporation System and method for collecting platelets and anticipating plasma return
US9364600B2 (en) 2008-04-14 2016-06-14 Haemonetics Corporation System and method for optimized apheresis draw and return
US9782707B2 (en) 2014-03-24 2017-10-10 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US9796166B2 (en) 2014-03-24 2017-10-24 Fenwal, Inc. Flexible biological fluid filters
US9968738B2 (en) 2014-03-24 2018-05-15 Fenwal, Inc. Biological fluid filters with molded frame and methods for making such filters
US10159778B2 (en) 2014-03-24 2018-12-25 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US10376627B2 (en) 2014-03-24 2019-08-13 Fenwal, Inc. Flexible biological fluid filters
US10758652B2 (en) 2017-05-30 2020-09-01 Haemonetics Corporation System and method for collecting plasma
US10792416B2 (en) 2017-05-30 2020-10-06 Haemonetics Corporation System and method for collecting plasma
US10946131B2 (en) 2018-05-21 2021-03-16 Fenwal, Inc. Systems and methods for optimization of plasma collection volumes
US11412967B2 (en) 2018-05-21 2022-08-16 Fenwal, Inc. Systems and methods for plasma collection
US11837357B2 (en) 2011-05-18 2023-12-05 Fenwal, Inc. Plasma collection with remote programming
US12033750B2 (en) 2018-05-21 2024-07-09 Fenwal, Inc. Plasma collection

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277337B1 (en) * 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344936A (en) * 1980-09-17 1982-08-17 Gerald Soslau Platelet composition having improved storage stability and method therefor
US4447415A (en) * 1982-11-01 1984-05-08 Rock Gail A Plasma-free medium for platelet storage
WO1986003122A1 (fr) * 1984-11-29 1986-06-05 Curatech, Inc. Agents cicatrisants
US4639373A (en) * 1984-11-29 1987-01-27 New England Medical Center Hospitals, Inc. Stabilization of granulocytes
EP0233112A1 (fr) * 1986-01-24 1987-08-19 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Procédé et dispositif pour séparer les éléments constitutifs du sang

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344936A (en) * 1980-09-17 1982-08-17 Gerald Soslau Platelet composition having improved storage stability and method therefor
US4447415A (en) * 1982-11-01 1984-05-08 Rock Gail A Plasma-free medium for platelet storage
WO1986003122A1 (fr) * 1984-11-29 1986-06-05 Curatech, Inc. Agents cicatrisants
US4639373A (en) * 1984-11-29 1987-01-27 New England Medical Center Hospitals, Inc. Stabilization of granulocytes
EP0233112A1 (fr) * 1986-01-24 1987-08-19 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Procédé et dispositif pour séparer les éléments constitutifs du sang

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024157A1 (fr) * 1992-05-29 1993-12-09 Baxter International Inc. Appareils et procedes pour generer un concentre plaquettaire depourvu de leucocytes
US5403272A (en) * 1992-05-29 1995-04-04 Baxter International Inc. Apparatus and methods for generating leukocyte free platelet concentrate
WO1994012223A1 (fr) * 1992-12-01 1994-06-09 Haemonetics Corporation Appareil et procede de pherese des globules rouges
US5387187A (en) * 1992-12-01 1995-02-07 Haemonetics Corporation Red cell apheresis method
EP0627228A1 (fr) * 1993-06-01 1994-12-07 ASAHI MEDICAL Co., Ltd. Centrifugeuse pour la séparation de produits sanguins et ses composants
US5547591A (en) * 1993-06-01 1996-08-20 Asahi Medical Co., Ltd. Method for separating a blood material into blood components by centrifugation, and centrifugal apparatus
US5637082A (en) * 1996-02-22 1997-06-10 Haemonetics Corporation Adaptive apheresis apparatus
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
EP1450892A2 (fr) * 2001-12-05 2004-09-01 Baxter International Inc. Systemes et procedes de traitement manuel permettant de fournir des constituants sanguins conditionnes en vue de l'inactivation pathogene
US6936413B1 (en) * 2001-12-05 2005-08-30 Baxter International Inc. Methods and systems for preparing blood products
EP1450892A4 (fr) * 2001-12-05 2005-11-30 Baxter Int Systemes et procedes de traitement manuel permettant de fournir des constituants sanguins conditionnes en vue de l'inactivation pathogene
US7264608B2 (en) 2001-12-05 2007-09-04 Fenwal, Inc. Manual processing systems and methods for providing blood components conditioned for pathogen inactivation
US9095665B2 (en) 2008-04-14 2015-08-04 Haemonetics Corporation Three-line apheresis system and method
US9364600B2 (en) 2008-04-14 2016-06-14 Haemonetics Corporation System and method for optimized apheresis draw and return
US8808217B2 (en) 2008-04-14 2014-08-19 Haemonetics Corporation System and method for plasma reduced platelet collection
WO2010039994A3 (fr) * 2008-10-01 2010-05-20 Caridianbct, Inc. Solution d’additif plaquettaire pour leucoréduction des leucocytes dans des plaquettes d’aphérèse
WO2010039994A2 (fr) * 2008-10-01 2010-04-08 Caridianbct, Inc. Solution d’additif plaquettaire pour leucoréduction des leucocytes dans des plaquettes d’aphérèse
US20100081985A1 (en) * 2008-10-01 2010-04-01 Caridianbct, Inc. Platelet Additive Solution For Leukoreducing White Blood Cells In Apheresed Platelets
US8834402B2 (en) 2009-03-12 2014-09-16 Haemonetics Corporation System and method for the re-anticoagulation of platelet rich plasma
US9248227B2 (en) 2009-03-12 2016-02-02 Haemonetics Corporation System and method for the re-anticoagulation of platelet rich plasma
US9789243B2 (en) 2009-03-12 2017-10-17 Haemonetics Corporation System and method for the re-anticoagulation of platelet rich plasma
CN101693039B (zh) * 2009-10-14 2011-12-14 北京普瑞博思投资有限公司 一种用于手术冲洗的药物组合物
US8808978B2 (en) 2010-11-05 2014-08-19 Haemonetics Corporation System and method for automated platelet wash
US9833794B2 (en) 2010-11-05 2017-12-05 Haemonetics Corporation System and method for automated platelet wash
US10806847B2 (en) 2010-12-30 2020-10-20 Haemonetics Corporation System and method for collecting platelets and anticipating plasma return
US9302042B2 (en) 2010-12-30 2016-04-05 Haemonetics Corporation System and method for collecting platelets and anticipating plasma return
US11837357B2 (en) 2011-05-18 2023-12-05 Fenwal, Inc. Plasma collection with remote programming
US9796166B2 (en) 2014-03-24 2017-10-24 Fenwal, Inc. Flexible biological fluid filters
US9968738B2 (en) 2014-03-24 2018-05-15 Fenwal, Inc. Biological fluid filters with molded frame and methods for making such filters
US10183475B2 (en) 2014-03-24 2019-01-22 Fenwal, Inc. Flexible biological fluid filters
US10343093B2 (en) 2014-03-24 2019-07-09 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US10376627B2 (en) 2014-03-24 2019-08-13 Fenwal, Inc. Flexible biological fluid filters
US10159778B2 (en) 2014-03-24 2018-12-25 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US9782707B2 (en) 2014-03-24 2017-10-10 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US11738124B2 (en) 2017-05-30 2023-08-29 Haemonetics Corporation System and method for collecting plasma
US12186474B2 (en) 2017-05-30 2025-01-07 Haemonetics Corporation System and method for collecting plasma
US10980926B2 (en) 2017-05-30 2021-04-20 Haemonetics Corporation System and method for collecting plasma
US10980934B2 (en) 2017-05-30 2021-04-20 Haemonetics Corporation System and method for collecting plasma
US12171916B2 (en) 2017-05-30 2024-12-24 Haemonetics Corporation System and method for collecting plasma
US10792416B2 (en) 2017-05-30 2020-10-06 Haemonetics Corporation System and method for collecting plasma
US10758652B2 (en) 2017-05-30 2020-09-01 Haemonetics Corporation System and method for collecting plasma
US11285251B2 (en) 2018-05-21 2022-03-29 Fenwal, Inc. Systems and methods for optimization of plasma collection volumes
US11383013B2 (en) 2018-05-21 2022-07-12 Fenwal, Inc. Systems and methods for optimization of plasma collection volumes
US11412967B2 (en) 2018-05-21 2022-08-16 Fenwal, Inc. Systems and methods for plasma collection
US11730873B2 (en) 2018-05-21 2023-08-22 Fenwal, Inc. Systems and methods for optimization of plasma collection volumes
US11369724B2 (en) 2018-05-21 2022-06-28 Fenwal, Inc. Systems and methods for optimization of plasma collection volumes
US11801001B2 (en) 2018-05-21 2023-10-31 Fenwal, Inc. Systems and methods for plasma collection
US11110216B2 (en) 2018-05-21 2021-09-07 Fenwal, Inc. Systems and methods for optimization of plasma collection volumes
US12033750B2 (en) 2018-05-21 2024-07-09 Fenwal, Inc. Plasma collection
US12083258B2 (en) 2018-05-21 2024-09-10 Fenwal, Inc. Systems and methods for optimization of plasma collection volumes
US12144624B2 (en) 2018-05-21 2024-11-19 Fenwal, Inc. Systems and methods for plasma collection
US11097042B2 (en) 2018-05-21 2021-08-24 Fenwal, Inc. Systems and methods for optimization of plasma collection volumes
US10946131B2 (en) 2018-05-21 2021-03-16 Fenwal, Inc. Systems and methods for optimization of plasma collection volumes
US12237078B2 (en) 2018-05-21 2025-02-25 Fenwal, Inc. Plasma collection

Also Published As

Publication number Publication date
KR900701290A (ko) 1990-12-01
JPH03505830A (ja) 1991-12-19
IT1217938B (it) 1990-03-30
AU3847589A (en) 1990-01-23
EP0447399A1 (fr) 1991-09-25
IT8821118A0 (it) 1988-06-28

Similar Documents

Publication Publication Date Title
WO1990000059A1 (fr) Procede et recipient servant a la preparation et au stockage de concentres de plaquettes
US4111199A (en) Method of collecting transfusable granulocytes by gravity leukopheresis
US4855063A (en) Red blood cell filtering system
US5236716A (en) Platelets concentrate with low white blood cells content
Eriksson et al. Platelet concentrates in an additive solution prepared from pooled buffy coats. In vitro studies
Högman et al. The bottom and top system: a new technique for blood component preparation and storage
EP0829267B1 (fr) Filtration à pré-stockage des plaquettes
US6527957B1 (en) Methods for separating, collecting and storing red blood cells
US4767541A (en) Method of removing platelets and white cells from a red cell concentrate
Valeri Simplification of the methods for adding and removing glycerol during freeze‐preservation of human red blood cells with the high or low glycerol methods: biochemical modification prior to freezing
Meryman et al. The preparation of red cells depleted of leukocytes: review and evaluation
US4915848A (en) Red blood cell filtering system
Lu et al. Traditional and emerging technologies for washing and volume reducing blood products
Eriksson et al. Platelet concentrates in an additive solution prepared from pooled buffy coats
Högman et al. Clinical and laboratory experience with erythrocyte and platelet preparations from a 0.5 CPD Erythro‐Sol opti system
JPS633867A (ja) 血液成分分離用血液バッグ
JP2002522007A (ja) 赤血球組成物、および赤血球を収集しそして保存するための方法
Buchholz Blood transfusion: Merits of component therapy: I. The clinical use of red cells, platelets, and granulocytes
Dragani et al. Comparison of five methods for concentrating progenitor cells in human marrow transplantation
Valbonesi et al. Erythrothrombocytapheresis and plasmathrombocytapheresis with storage in T-sol of platelets collected by the new Amicus cell separator
Gulliksson et al. A system for the supply of platelets suspended in a storage medium including buffy-coat-derived platelet concentrates in combination with “split” apheresis platelets
Aisner et al. Gravity leukapheresis—A simple method of leukocyte collection for transfusion or in vitro study
WO1993007745A1 (fr) Procede pour congeler des cellules de greffage
Högman et al. A simple method for the preparation of microaggregate‐poor whole blood
JPH09168585A (ja) 血液バッグシステム

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BE DE FR GB IT NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989907257

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989907257

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989907257

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载